Dyax to Present at BIO 2003 Annual Convention.

Business Editors/Health/Medical Writers

BIO 2003 Annual Convention

BIOWIRE2

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 20, 2003

Dyax Corp. (Nasdaq:DYAX) announced today that Henry Blair, Chairman, President and Chief Executive Officer, will present an update

of Dyax's Phase II clinical development programs at BIO 2003, the annual convention of the Biotechnology Industry Organization. The conference is being held at the Washington Convention Center in Washington, D.C. from June 22-25, 2003. Mr. Blair will be presenting during the Business Forum (Room B) on Tuesday, June 24 at 9:15 a.m.

The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at http://www.dyax.com. The 15-minute presentation will be available on the Dyax website for a limited period of time following the conference.

Dyax Corp.

Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic antibodies, small proteins and peptides to be used as anti-inflammatory agents and in oncology. Dyax currently has two recombinant proteins in phase II clinical trials. DX-88 is in phase II studies for the potential treatment of hereditary angioedema, and in phase I/II studies for use during cardiopulmonary bypass surgery. DX-890 is in phase II clinical trials for the potential treatment of cystic fibrosis. The Company uses its patented phage display technology to rapidly identify compounds that bind with high affinity and specificity to targets of interest, with the objective of advancing those with the greatest therapeutic potential into clinical development. Dyax leverages its technology broadly through revenue generating licenses and collaborations in therapeutics and in non-core areas of affinity separations, diagnostic imaging, and research reagents. Through its subsidiary, Biotage, Inc., Dyax develops, manufactures and sells its novel cartridge- based chromatography drug purification and separations systems as tools to speed the drug discovery process at pharmaceutical companies worldwide. For more information on Dyax Corp., please visit the Company's website at www.dyax.com.

Dyax and the Dyax logo are registered trademarks of Dyax Corp. Biotage is a trademark of Biotage, Inc., a Dyax subsidiary.